A recent study found that a non-invasive test based on carbon monoxide could help diagnose HDFN earlier and improve outcomes.

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Kozhikode: A preliminary study conducted by the National Institute of Virology (NIV) in Pune indicates that there has been no ...